O2Medi develops a photodynamic therapy platform that utilizes iridium-based photosensitizers to generate reactive oxygen species in hypoxic tumor environments, effectively inducing cell death in cancer cells. This technology addresses the challenge of low oxygen levels in tumors, enhancing the efficacy of cancer treatments, particularly for difficult-to-treat conditions like pancreatic cancer.
Funding
Funding not disclosed
Founders
Product
Problem
Many tumors, particularly aggressive cancers like pancreatic cancer, have low oxygen levels (hypoxia), which reduces the effectiveness of traditional cancer treatments. Existing photodynamic therapies struggle to generate sufficient reactive oxygen species in these hypoxic tumor microenvironments, limiting their ability to induce cancer cell death.
Solution
O2Medi is developing a photodynamic therapy platform that uses iridium-based photosensitizers to overcome hypoxia in tumors and enhance cancer treatment efficacy. The platform's core technology involves a novel mechanism to generate hydroxyl radicals, a potent reactive oxygen species, by decomposing water molecules within the hypoxic tumor environment. By producing reactive oxygen species directly within the tumor, O2Medi's approach aims to selectively induce pyroptosis, an immunogenic form of cell death, in cancer cells, even in oxygen-deprived conditions. This targeted approach seeks to improve treatment outcomes for difficult-to-treat cancers while also stimulating an anti-tumor immune response.
Target Audience
The primary target audience includes patients with difficult-to-treat cancers, such as pancreatic cancer, and oncologists seeking more effective therapies for hypoxic tumors.
Features
- Iridium-based photosensitizers designed to be activated by light within the tumor microenvironment
- Technology to generate hydroxyl radicals by water decomposition, bypassing the need for oxygen
- Selective induction of pyroptosis in cancer cells, promoting an anti-tumor immune response
- Potential application as a platform technology applicable to various cancer types
- Preclinical studies demonstrating effective tumor reduction in pancreatic cancer animal models